Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ジキニンファーストネオCZ
- Development stage
- Unknown
- Lead developer
- Zenyaku Kogyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ジキニンファーストネオCZ (Jikinin First Neo CZ) is a multi-symptom over-the-counter (OTC) cold medication developed and marketed by Zenyaku Kogyo (Zenyaku Holdings) in Japan. It is formulated as a combination product to alleviate various symptoms associated with the common cold, including fever, sore throat, cough, and nasal congestion. The formulation typically contains seven active ingredients: ibuprofen (analgesic and antipyretic), tranexamic acid (anti-inflammatory for throat pain), bromhexine hydrochloride (mucolytic/expectorant), dihydrocodeine phosphate (antitussive), dl-methylephedrine hydrochloride (bronchodilator), chlorpheniramine maleate (antihistamine), and anhydrous caffeine. It is classified as a Designated Class 2 OTC drug in Japan and is administered orally, usually in tablet form.
- Brand names
- ジキニンファーストネオCZJikinin First Neo CZ
02
Targets
ADOR (Adenosine receptors)HRH1 (Histamine H1 Receptor)TUBB (Tubulin (alpha and beta subunits))MOR (Mu opioid receptor)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)PLG (Plasminogen)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on ジキニンファーストネオCZ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ジキニンファーストネオCZ.